Paper Details

  1. Home
  2. Paper Details

Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation.

Author: BeckaMichael, KubitzaDagmar, MueckWolfgang

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Rivaroxaban (BAY 59-7939) is a novel, oral, direct Factor Xa inhibitor being developed for the prevention and treatment of thromboembolic disorders. Pro-arrhythmic effects are a common reason for drugs failing to gain regulatory approval, so the effect of rivaroxaban on the QT interval was assessed.
Paper Details　
Original Abstract of the Article :
Rivaroxaban (BAY 59-7939) is a novel, oral, direct Factor Xa inhibitor in advanced clinical development for the prevention and treatment of thromboembolic disorders. Unwanted pro-arrhythmic effects are a common reason for drugs failing to gain regulatory approval; these properties can be detected by...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2165/00002018-200831010-00006

データ提供：米国国立医学図書館（NLM）

Rivaroxaban and Its Effect on the QT Interval

In the vast and ever-evolving desert of cardiovascular research, we're constantly searching for new and effective medications to combat heart disease. This study investigates the potential impact of rivaroxaban, a novel oral anticoagulant, on the QT interval, a measure of electrical activity in the heart. The researchers aimed to assess the safety of rivaroxaban by evaluating its effect on the QT interval, a potential marker of pro-arrhythmic risk.

A Safe Passage Through the Desert of Anticoagulation

The study, conducted using a randomized, double-blind, crossover design, revealed that rivaroxaban did not significantly prolong the QT interval in healthy volunteers. This finding offers reassurance about the safety of rivaroxaban, a medication that holds promise for the prevention and treatment of thromboembolic disorders. The researchers found that rivaroxaban did not significantly prolong the QT interval in healthy volunteers. This finding offers reassurance about the safety of rivaroxaban, a medication that holds promise for the prevention and treatment of thromboembolic disorders.

A Beacon of Hope in the Desert of Cardiovascular Disease

This research offers valuable insights into the safety profile of rivaroxaban, a medication that could potentially benefit a wide range of individuals at risk for blood clots. By understanding the impact of medications on the QT interval, we can make informed decisions about treatment and minimize the risk of potential complications. This study is a testament to the importance of careful and thorough research in ensuring the safety and effectiveness of new medications.

Dr.Camel's Conclusion

This study provides reassuring evidence regarding the safety of rivaroxaban, a promising new anticoagulant. The findings highlight the importance of carefully assessing the potential impact of medications on the QT interval to ensure patient safety.

Date :
  1. Date Completed 2008-05-05
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

18095747

DOI: Digital Object Identifier

10.2165/00002018-200831010-00006

Related Literature

Article Analysis
・Effects of rivaroxaban
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.